Overview
Background
David is a passionate and driven scientist with a successful track record in translational commercially focused technical and academic leadership. David has worked in academia and industry at the interface of chemistry, biochemistry and biology. He has successfully designed and developed several oncology nanomedicines and driven them forward into clinical trials.
As Director of the Protein Expression Facility (PEF) within The University of Queensland, David and his team strive to build collaborations and provide excellent service provision with a wide variety of researchers across academia and industry. Through this work we ensure PEF achieves its vision to be a world leader in protein research services and innovative solutions for protein production driving scientific success.
Availability
- Professor David Owen is:
- Available for supervision
Research interests
-
Protein Science
-
Nanotechnology
-
Radiotheranostics
-
Cancer Biology
-
Bioconjugation
Works
Search Professor David Owen’s works on UQ eSpace
2023
Journal Article
In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate
Sonzini, Silvia, Caputo, Fanny, Mehn, Dora, Calzolai, Luigi, Even Borgos, Sven, Hyldbakk, Astrid, Treacher, Kevin, Li, Weimin, Jackman, Mark, Mahmoudi, Najet, Jayne Lawrence, M., Patterson, Claire, Owen, David, Ashford, Marianne and Akhtar, Nadim (2023). In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate. International Journal of Pharmaceutics, 637 122905, 1-14. doi: 10.1016/j.ijpharm.2023.122905
2022
Journal Article
Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma
Feeney, Orlagh M., Ardipradja, Katie, Noi, Ka Fung, Mehta, Dharmini, De Rose, Robert, Yuen, Daniel, Johnston, Angus P.R., Kingston, Lee, Ericsson, Cecilia, Elmore, Charles S., Hufton, Richard, Owen, David J., Ashford, Marianne B. and Porter, Christopher J.H. (2022). Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma. Journal of Controlled Release, 348, 420-430. doi: 10.1016/j.jconrel.2022.05.041
2021
Journal Article
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Patterson, Claire M., Balachander, Srividya B., Grant, Iain, Pop-Damkov, Petar, Kelly, Brian, McCoull, William, Parker, Jeremy, Giannis, Michael, Hill, Kathryn J., Gibbons, Francis D., Hennessy, Edward J., Kemmitt, Paul, Harmer, Alexander R., Gales, Sonya, Purbrick, Stuart, Redmond, Sean, Skinner, Matthew, Graham, Lorraine, Secrist, J. Paul, Schuller, Alwin G., Wen, Shenghua, Adam, Ammar, Reimer, Corinne, Cidado, Justin, Wild, Martin, Gangl, Eric, Fawell, Stephen E., Saeh, Jamal, Davies, Barry R. ... Ashford, Marianne B. (2021). Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Communications Biology, 4 (1) 112, 112. doi: 10.1038/s42003-020-01631-8
2020
Conference Publication
Anti-cancer activity of a SN-38 nanoparticle, DEP® irinotecan, in human colon cancer xenograft models
Kelly, Brian D., McLeod, Victoria, Walker, Rachael, Schreuders, Jeannette, Jackson, Susan, Giannis, Michael, Dietinger, Christine, Xia, Shirley, Cargill, Anne, Seta, Aynaz, Hufton, Richard, Heery, Graham, Cullinane, Carleen and Owen, David J. (2020). Anti-cancer activity of a SN-38 nanoparticle, DEP® irinotecan, in human colon cancer xenograft models. AACR Annual Meeting 2020, Philadelphia, PA United States, 27-28 April 2020. Philadelphia, PA United States: American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.am2020-1715
2020
Conference Publication
Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index
Ashford, Marianne B., Balachander, Srividya B., Graham, Lorraine, Grant, Iain, Gibbons, Francis D., Hill, Kathryn J., Harmer, Alexander R., Gales, Sonya, Redmond, Sean, Kelly, Brian, McCoull, William, Wen, Shenghua, Wild, Martin, Gangl, Eric, Owen, David J. and Davies, Barry R. (2020). Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index. AACR Annual Meeting 2020, Philadelphia, PA United States, 27-28 April 2020. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-1718
2020
Conference Publication
Anticancer activity of the taxane nanoparticles, DEP® docetaxel and DEP® cabazitaxel
Kelly, Brian D., McLeod, Victoria, Walker, Rachael, Schreuders, Jeannette, Jackson, Susan, Giannis, Michael, Dietinger, Christine, Reitano, Pauline, Pathak, Rashmi, Xia, Shirley, Cargill, Anne, Seta, Aynaz, Hufton, Richard, Heery, Graham, Cullinane, Carleen and Owen, David J. (2020). Anticancer activity of the taxane nanoparticles, DEP® docetaxel and DEP® cabazitaxel. AACR Annual Meeting 2020, Philadelphia, PA United States, 27-28 April 2020. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-1716
2020
Other Outputs
Dendrimer-drug conjugates
Owen, David James, Stanislsawski, Pauline, Giannis, Michael and Bernhard, Oliver (2020). Dendrimer-drug conjugates.
2018
Journal Article
Reducing dendrimer generation and PEG chain length increases drug release and promotes anti-cancer activity of PEGylated polylysine dendrimers conjugated with doxorubicin via a cathepsin-cleavable peptide linker
Mehta, Dharmini, Leong, Nathania, McLeod, Victoria M., Kelly, Brian D., Pathak, Rashmi, Owen, David J., Porter, Christopher J.H. and Kaminskas, Lisa M. (2018). Reducing dendrimer generation and PEG chain length increases drug release and promotes anti-cancer activity of PEGylated polylysine dendrimers conjugated with doxorubicin via a cathepsin-cleavable peptide linker. Molecular Pharmaceutics, 15 (10) acs.molpharmaceut.8b00581, 4568-4576. doi: 10.1021/acs.molpharmaceut.8b00581
2018
Journal Article
Doxorubicin conjugation and drug linker chemistry alter the intravenous and pulmonary pharmacokinetics of a PEGylated Generation 4 polylysine dendrimer in rats
Leong, Nathania J., Mehta, Dharmini, McLeod, Victoria M., Kelly, Brian D., Pathak, Rashmi, Owen, David J., Porter, Christopher J. H. and Kaminskas, Lisa M. (2018). Doxorubicin conjugation and drug linker chemistry alter the intravenous and pulmonary pharmacokinetics of a PEGylated Generation 4 polylysine dendrimer in rats. Journal of Pharmaceutical Sciences, 107 (9), 2509-2513. doi: 10.1016/j.xphs.2018.05.013
2017
Journal Article
Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site
Ryan G.M., McLeod V.M., Mehta D., Kelly B.D., Stanislawski P.C., Owen D.J., Kaminskas L.M. and Porter C.J.H. (2017). Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site. Nanomedicine: Nanotechnology, Biology and Medicine, 13 (8), 2485-2494. doi: 10.1016/j.nano.2017.08.003
2017
Journal Article
Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers
Haque, Shadabul, McLeod, Victoria M., Jones, Seth, Fung, Sandy, Whittaker, Michael, McIntosh, Michelle, Pouton, Colin, Owen, David J., Porter, Christopher J. H. and Kaminskas, Lisa M. (2017). Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. European Journal of Pharmaceutics and Biopharmaceutics, 119, 408-418. doi: 10.1016/j.ejpb.2017.07.005
2017
Other Outputs
Macromolecules
Owen, David (2017). Macromolecules.
2016
Journal Article
A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated dendrimer following intravenous and aerosol administration to rats and sheep
Ryan, Gemma M., Bischof, Robert J., Enkhbaatar, Perenlei, McLeod, Victoria M., Chan, Linda J., Jones, Seth A., Owen, David J., Porter, Christopher J. H. and Kaminskas, Lisa M. (2016). A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated dendrimer following intravenous and aerosol administration to rats and sheep. Pharmaceutical Research, 33 (2), 510-525. doi: 10.1007/s11095-015-1806-z
2015
Journal Article
Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats
Kaminskas, Lisa M., McLeod, Victoria M., Ascher, David B., Ryan, Gemma M., Jones, Seth, Haynes, John M., Trevaskis, Natalie L., Chan, Linda J., Sloan, Erica K., Finnin, Benjamin A., Williamson, Mark, Velkov, Tony, Williams, Elizabeth D., Kelly, Brian D., Owen, David J. and Porter, Christopher J. H. (2015). Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats. Molecular Pharmaceutics, 12 (2), 432-443. doi: 10.1021/mp500531e
2014
Journal Article
Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy
Kaminskas, Lisa M., McLeod, Victoria M., Ryan, Gemma M., Kelly, Brian D., Haynes, John M., Williamson, Mark, Thienthong, Neeranat, Owen, David J. and Porter, Christopher J. H. (2014). Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. Journal of Controlled Release, 183 (1), 18-26. doi: 10.1016/j.jconrel.2014.03.012
2013
Journal Article
PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin
Ryan, Gemma M., Kaminskas, Lisa M., Bulitta, Juergen B., McIntosh, Michelle P., Owen, David J. and Porter, Christopher J. H. (2013). PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. Journal of Controlled Release, 172 (1), 128-136. doi: 10.1016/j.jconrel.2013.08.004
2013
Journal Article
Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent
Ryan, Gemma M., Kaminskas, Lisa M., Kelly, Brian D., Owen, David J., McIntosh, Michelle P. and Porter, Christopher J. H. (2013). Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Molecular Pharmaceutics, 10 (8), 2986-2995. doi: 10.1021/mp400091n
2012
Journal Article
Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models
Kaminskas, Lisa M., McLeod, Victoria M., Kelly, Brian D., Cullinane, Carleen, Sberna, Gian, Williamson, Mark, Boyd, Ben J., Owen, David J. and Porter, Christopher J. H. (2012). Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Molecular Pharmaceutics, 9 (3), 422-432. doi: 10.1021/mp200522d
2012
Journal Article
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems
Kaminskas, Lisa M., McLeod, Victoria M., Kelly, Brian D., Sberna, Gian, Boyd, Ben J., Williamson, Mark, Owen, David J. and Porter, Christopher J. H. (2012). A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine: Nanotechnology, Biology and Medicine, 8 (1), 103-111. doi: 10.1016/j.nano.2011.05.013
2011
Journal Article
Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker
Kaminskas, Lisa M., Kelly, Brian D., McLeod, Victoria M., Sberna, Gian, Owen, David J., Boyd, Ben J. and Porter, Christopher J. H. (2011). Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. Journal of Controlled Release, 152 (2), 241-248. doi: 10.1016/j.jconrel.2011.02.005
Supervision
Availability
- Professor David Owen is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
The Molecular Characterisation of Myeloperoxidase (MPO) and its role in autoimmunity
Principal Advisor
Other advisors: Professor Ranjeny Thomas, Associate Professor Fiona Simpson, Dr Pie Huda
-
Doctor Philosophy
Development of a versatile targeted alpha therapy platform
Associate Advisor
Other advisors: Dr Nick Fletcher, Dr Pie Huda
-
Doctor Philosophy
mRNA therapies for liver disorders
Associate Advisor
Other advisors: Dr Seth Cheetham
-
Doctor Philosophy
Assessment of Nanomedicine Efficacy and Mechanism using Metabolic Spectroscopic Imaging.
Associate Advisor
Other advisors: Associate Professor Idriss Blakey
-
Doctor Philosophy
Broad Spectrum Medical Countermeasure development for Organophosphate Compounds
Associate Advisor
Other advisors: Professor Linda Lua
Media
Enquiries
For media enquiries about Professor David Owen's areas of expertise, story ideas and help finding experts, contact our Media team: